Adjuvant Kemoterapi Almış FIGO 2014 Evre II Yüksek-Grade Seröz Over Kanseri Olan 49 Hastanın Klinikopatolojik Özellikleri
Abstract
Amaç: Evre 2 yüksek-grade seröz over kanseri tanısı alan ve cerrahi sonrasında adjuvant kemoterapi alan hastaların klinikopatolojik özellikleri ve nüks paternlerinin araştırılması amaçlanmıştır.
Gereç ve Yöntem: Kliniğimizde 1993-2021 yılları arasında tedavi görmüş, yüksek-grade seröz over kanseri nedeniyle total abdominal histerektomi + bilateral salpingooferektomi + pelvik-paraaortik lenf nodu diseksiyonu +/- omentektomi yapılan, adjuvan kemoterapi alan, FIGO 2014 evreleme sistemine göre evre 2 olan, 49 hasta çalışmaya dahil edilmiştir.
Bulgular: Hastaların evre dağılımı değerlendirildiğinde, evre IIA olan 27 hasta (%55,1), IIB olan 22 hasta (%44,9) idi. 49 hastanın 16’sında (%28,6) rekürrens gelişti. Rekürrens gelişen hastalarda nüks gelişen bölgelere bakıldığında sadece pelvik 3 (%6,1), sadece abdomen 12 (%24,5) iken abdominal + pelvik nüks 1 (%2) hastada gelişti. Nüks gelişen 7 hastaya kemoterapi verilirken, 1 hastaya sekonder sitoredüksiyon uygulandı. 8 hastaya ise sekonder sitoredüksiyona ek olarak kemoterapi verildi.
Sonuç: Kliniğimizde 1170 hasta seröz over kanseri nedeniyle opere edilmiş olup bunların sadece 49 (% 4,18) tanesi yüksek gradeli, FIGO 2014 evreleme sistemine göre evre 2 kanserdir. Çalışmamıza dahil olan hastalarda nüks oranı %28,6’ dır. Nüks gelişen 7 hasta evre 2A (%43,75), 9 hasta evre 2B (%56,25) idi. Hastalığın nüksü %75 oranında batında görülmüştür. Evre 2 hastalarda nüks oranı azımsanamayacak derecede yüksektir. Bu nüksler sağkalımı yakından ilgilendirmektedir.
Keywords
Thanks
Teşekkür ederiz.
References
- 1. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014 Jan;124(1):1-5.
- 2. Heintz APM, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. In FIGO annual report on the results of treatment in gynecological cancer. Int J Obstet Gynecol 2006;95:S161
- 3. Torre LA, Trabert B, DeSantis CE ve ark. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296.
- 4. Trimbos JB, Schueler JA. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer 1991;67:597-602
- 5. Ye S, Yang J, You Y ve ark. Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS One 2015;10(7):e0133498.
- 6. Organization WH. WHO handbook for reporting results of cancer treatment: World Health Organization; 1979.
- 7. Robboy, S.J., Robboy's pathology of the female reproductive tract. 2009: Elsevier Health Sciences.
- 8. S. Lheureux, C. Gourley, I. Vergote ve ark. Epithelial ovarian cancer, Lancet 2019; 393: 1240–53
- 9. Bahadır Saatli , Turab Janbakhisov , Özlen Emekçi ve ark. Peritoneal karsinomatoza bulgusu olmayan çok yüksek serum CA 125 değeri olan adneksiyal kitlelerin klinikopatolojik değerlendirilmesi, Dokuz Eylül Tıp Fakültesi Dergisi 2013;27(1):33-38
- 10. Yetimalar H, Köksal A, Uğur H, ve ark. Transvaginal ultrasonografi ile adneks kitlelerinin benignmalign ayrımının yapılması [Malign or benign differantial diagnosis of adnexial masses with transvaginal ultrasonography]. T Klin Obstet 2001;11:174-179.
- 11. Tropé C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007(25):2909–20.
- 12. J.K. Chan, C. Tian, B.J. Monk ve ark., Prognostic factors for high-risk earlystage epithelial ovarian cancer: a Gynecologic Oncology Group study, Cancer 112 (10) (2008) 2202–2210.
- 13. Amate P, Huchon C, Dessapt AL ve ark. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013 Nov;23(9):1590-6.
Clinicopathological Characteristics of 49 Patients with FIGO 2014 Stage II High-Grade Serous Ovarian Cancer Who Received Adjuvant Chemotherapy
Abstract
Objective: We aimed to investigate the clinicopathological features and recurrence patterns of patients who were diagnosed with stage 2 high-grade serous ovarian cancer and received adjuvant chemotherapy after surgery.
Material and Methods: 49 patients treated in our clinic between 1993-2021, who underwent total abdominal hysterectomy + bilateral salpingo-oophorectomy + pelvic-paraaortic lymph node dissection +/- omentectomy for high-grade serous ovarian cancer, received adjuvant chemotherapy, who were stage 2 according to the FIGO 2014 staging system was included in the study.
Results: When the stage distribution of the patients was evaluated, stage IIA was detected 27 patients (55.1%), and IIB was detected 22 patients (44.9%). Recurrence developed in 16 (28.6%) of 49 patients (27 patients had stage IIA, 22 patients had IIB) Considering the recurrence areas of the patients with recurrence, only pelvic 3 (6,1%), only the abdomen 12 (24,5%), while abdominal + pelvic recurrence developed in 1 (2%) patient. While chemotherapy was given to 7 patients who developed relapse, secondary cytoreduction was applied to 1 patient. Chemotherapy was given to 8 patients in addition to secondary cytoreduction.
Conclusion: In our clinic, 1170 patients were operated for serous ovarian cancer, and only 49 (4.18%) of them were high grade, stage 2 cancer according to the FIGO 2014 staging system. The recurrence rate in the patients included in our study was 28.6%. 7 patients who developed relapse were stage 2A (43.75%), and 9 patients were stage 2B (56.25%). The recurrence of the disease was seen in the abdomen at a rate of 75%. The recurrence rate in stage 2 patients is considerably high. These recurrences are closely related to survival.
Keywords
References
- 1. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014 Jan;124(1):1-5.
- 2. Heintz APM, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. In FIGO annual report on the results of treatment in gynecological cancer. Int J Obstet Gynecol 2006;95:S161
- 3. Torre LA, Trabert B, DeSantis CE ve ark. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296.
- 4. Trimbos JB, Schueler JA. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer 1991;67:597-602
- 5. Ye S, Yang J, You Y ve ark. Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS One 2015;10(7):e0133498.
- 6. Organization WH. WHO handbook for reporting results of cancer treatment: World Health Organization; 1979.
- 7. Robboy, S.J., Robboy's pathology of the female reproductive tract. 2009: Elsevier Health Sciences.
- 8. S. Lheureux, C. Gourley, I. Vergote ve ark. Epithelial ovarian cancer, Lancet 2019; 393: 1240–53
- 9. Bahadır Saatli , Turab Janbakhisov , Özlen Emekçi ve ark. Peritoneal karsinomatoza bulgusu olmayan çok yüksek serum CA 125 değeri olan adneksiyal kitlelerin klinikopatolojik değerlendirilmesi, Dokuz Eylül Tıp Fakültesi Dergisi 2013;27(1):33-38
- 10. Yetimalar H, Köksal A, Uğur H, ve ark. Transvaginal ultrasonografi ile adneks kitlelerinin benignmalign ayrımının yapılması [Malign or benign differantial diagnosis of adnexial masses with transvaginal ultrasonography]. T Klin Obstet 2001;11:174-179.
- 11. Tropé C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007(25):2909–20.
- 12. J.K. Chan, C. Tian, B.J. Monk ve ark., Prognostic factors for high-risk earlystage epithelial ovarian cancer: a Gynecologic Oncology Group study, Cancer 112 (10) (2008) 2202–2210.
- 13. Amate P, Huchon C, Dessapt AL ve ark. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013 Nov;23(9):1590-6.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Obstetrics and Gynaecology |
| Journal Section | Research Article |
| Authors | |
| Publication Date | June 30, 2022 |
| Acceptance Date | June 28, 2022 |
| Published in Issue | Year 2022 Volume: 4 Issue: 2 |
